Comerica Bank sold its interest in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) down 10.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund held 33,486 shares of the company’s stock after selling 3,722 shares during the period. Comerica Bank owned 0.08% of Meridian Bioscience worth $1,071,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
→ The next big crisis is here (From Porter & Company)
Other institutional investors and hedge funds have also made changes to their holdings in the company. JPMorgan Chase & Co. increased its stake in Meridian Bioscience by 16.1% during the first quarter. JPMorgan Chase & Co. now owns 156,631 shares of the company’s stock valued at $4,067,000 after purchasing an additional 21,777 shares during the last quarter. American Century Companies Inc. increased its exposure to shares of Meridian Bioscience by 11.1% during the first quarter. American Century Companies Inc. now owns 54,644 shares of the company’s stock valued at $1,419,000 after purchasing an additional 5,463 shares during the last quarter. Citi Group Inc. increased its stake in Meridian Bioscience shares by 2.5% in the first quarter. Citi Group Inc. now owns 48,835 shares of the company’s stock valued at $1,268,000 after purchasing an additional 1,200 shares in the last quarter. Bank of Montreal Can increased its exposure to shares of Meridian Bioscience by 7.2% in the first quarter. Bank of Montreal Can now owns 14,144 shares of the company’s stock worth $383,000 after purchasing an additional 955 shares during the last quarter. Finally, MetLife Investment Management LLC increased its exposure to shares of Meridian Bioscience by 57.9% in the first quarter. MetLife Investment Management LLC now owns 23,227 shares of the company’s stock valued at $603,000 after purchasing an additional 8,516 shares in the last quarter. 89.72% of the shares are held by institutional investors and hedge funds.
Meridian Bioscience Stock Performance
Shares of VIVO opened Wednesday at $33.76. The company’s 50-day simple moving average is $32.82 and its 200-day simple moving average is $32.45. Meridian Bioscience, Inc. has a 12-month low of $19.91 and a 12-month high of $34.38. The company has a market cap of $1.48 billion, a PE ratio of 34.80 and a beta of 0.26. The company has a current ratio of 3.63, a quick ratio of 2.46 and a debt-to-equity ratio of 0.07.
Meridian Bioscience (NASDAQ:VIVO – Get Rating) last published its quarterly results on Tuesday, November 22. The company reported earnings per share of $0.20 for the quarter, beating analyst consensus estimates of $0.15 by $0.05. Meridian Bioscience had a net margin of 12.70% and a return on equity of 16.74%. The company had revenue of $65.68 million for the quarter, compared to analyst estimates of $67.45 million. As a group, equity analysts predict that Meridian Bioscience, Inc. will record 0.83 EPS for the current year.
Changes in analyst ratings
VIVO has been the subject of a number of research reports. William Blair reissued a “market perform” rating for shares of Meridian Bioscience in a research report on Friday, Nov. 25. StockNews.com downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, Nov. 19.
Meridian Bioscience Profile
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes and markets diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company operates through the Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the brand name Curian; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic strip voltammetry under the LeadCare brands; and urea breath tests for H.
This instant news alert is generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest, most accurate reporting. This story has been reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Meridian Bioscience, you want to hear this.
MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Meridian Bioscience was not on the list.
While Meridian Bioscience currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View the five stocks here